Sunesis Pharmaceuticals, Inc. (SNSS)-Financial and Strategic SWOT Analysis Review

Sunesis Pharmaceuticals, Inc. (SNSS)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH33264FSA
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sunesis Pharmaceuticals, Inc. (SNSS)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sunesis Pharmaceuticals, Inc. (Sunesis), formerly Mosaic Pharmaceuticals, Inc., is a biopharmaceutical company. It develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's lead product candidate Qinprezo (vosaroxin) is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase II clinical trials for the treatment of myelodysplastic syndromes (MDS). The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in California, the US.

Sunesis Pharmaceuticals, Inc. Key Recent Developments

Jul 29, 2016: Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights

Jun 06, 2016: Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting

Jun 01, 2016: Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development

May 05, 2016: Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights

Mar 28, 2016: Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Sunesis Pharmaceuticals, Inc.-Key Facts 6

Sunesis Pharmaceuticals, Inc.-Key Employees 7

Sunesis Pharmaceuticals, Inc.-Key Employee Biographies 8

Sunesis Pharmaceuticals, Inc.-Major Products and Services 10

Sunesis Pharmaceuticals, Inc.-Pharmaceutical Pipeline Products Data 11

Sunesis Pharmaceuticals, Inc., Pipeline Products by Therapy Area 11

Sunesis Pharmaceuticals, Inc., Pipeline Products by Development Phase 12

Sunesis Pharmaceuticals, Inc.-History 14

Sunesis Pharmaceuticals, Inc.-Company Statement 17

Sunesis Pharmaceuticals, Inc.-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Section 2-Company Analysis 19

Sunesis Pharmaceuticals, Inc.-Business Description 19

Sunesis Pharmaceuticals, Inc.-Corporate Strategy 20

Sunesis Pharmaceuticals, Inc.-SWOT Analysis 21

SWOT Analysis-Overview 21

Sunesis Pharmaceuticals, Inc.-Strengths 21

Strength-Focused Research and Development Activities 21

Strength-Lead Candidate: Qinprezo (vosaroxin) 21

Strength-Agreements and Collaborations 21

Sunesis Pharmaceuticals, Inc.-Weaknesses 22

Weakness-Lack of Marked Products 22

Weakness-Competitive Positioning 22

Weakness-Additional Studies 22

Sunesis Pharmaceuticals, Inc.-Opportunities 23

Opportunity-Orphan Drug & Fast Track Designation 23

Opportunity-Strategic Agreement 23

Opportunity-Market Potential: Acute Myeloid Leukemia 23

Sunesis Pharmaceuticals, Inc.-Threats 24

Threat-Intense Competition 24

Threat-Patent Expiries 24

Threat-Lack of Manufacturing Facilities 24

Sunesis Pharmaceuticals, Inc.-Key Competitors 25

Section 3-Company Financial Ratios 26

Financial Ratios-Capital Market Ratios 26

Financial Ratios-Annual Ratios 27

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 32

Sunesis Pharmaceuticals, Inc., Recent Deals Summary 33

Section 5-Company's Recent Developments 34

Jul 29, 2016: Sunesis Pharmaceuticals Reports Second Quarter 2016 Financial Results and Recent Highlights 34

Jun 06, 2016: Sunesis Announces Study Examining the Value of Complete Remission Prior to HCT in Patients with AML Presented at 2016 ASCO Annual Meeting 36

Jun 01, 2016: Sunesis Pharmaceuticals Appoints Linda Neuman, M.D., as Vice President, Clinical Development 37

May 05, 2016: Sunesis Pharmaceuticals Reports First Quarter 2016 Financial Results and Recent Highlights 38

Mar 28, 2016: Sunesis Pharmaceuticals Appoints Geoffrey Parker to the Board of Directors 40

Mar 10, 2016: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results and Recent Highlights 41

Feb 19, 2016: Sunesis Pharmaceuticals Announces Promotion of Deborah A. Thomas, Ph.D., to Senior Vice President, Regulatory Affairs, Quality Assurance, and Non-Clinical Development 43

Nov 05, 2015: Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights 44

Jul 30, 2015: Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights 47

May 05, 2015: Sunesis Pharmaceuticals Reports First Quarter 2015 Financial Results and Recent Highlights 49

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

Sunesis Pharmaceuticals, Inc., Pipeline Products by Therapy Area 11

Sunesis Pharmaceuticals, Inc., Pipeline Products by Development Phase 12

Sunesis Pharmaceuticals, Inc., Performance Chart (2011-2015) 28

Sunesis Pharmaceuticals, Inc., Ratio Charts 30

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 32

List of Tables

Sunesis Pharmaceuticals, Inc., Key Facts 6

Sunesis Pharmaceuticals, Inc., Key Employees 7

Sunesis Pharmaceuticals, Inc., Key Employee Biographies 8

Sunesis Pharmaceuticals, Inc., Major Products and Services 10

Sunesis Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 11

Sunesis Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 12

Sunesis Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 13

Sunesis Pharmaceuticals, Inc., History 14

Sunesis Pharmaceuticals, Inc., Subsidiaries 18

Sunesis Pharmaceuticals, Inc., Key Competitors 25

Sunesis Pharmaceuticals, Inc., Ratios based on current share price 26

Sunesis Pharmaceuticals, Inc., Annual Ratios 27

Sunesis Pharmaceuticals, Inc., Interim Ratios 29

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 31

Sunesis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 32

Sunesis Pharmaceuticals, Inc., Recent Deals Summary 33

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Sunesis Pharmaceuticals, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8060
Site License
USD 250 INR 16120
Corporate User License
USD 375 INR 24180

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com